Concepedia

Author

Günter Henze

Charité - Universitätsmedizin Berlin

Also Known As

G Henze, G. . Henze, G. Henze, Gunter Henze, Gunter Henze,, Günter Henze, GÜNter Henze, Günter H.R. Henze, Günter Henze, Joachim Boos

232

Publications

10.8K

Citations

48

H-Index

153

Concepts

All Affiliations

Charité - Universitätsmedizin BerlinHumboldt-Universität zu BerlinMedizinische Hochschule HannoverHeinrich Heine University DüsseldorfGoethe University Frankfurt
GH

About

Günter Henze is an author at Charité - Universitätsmedizin Berlin specializing in medicine, oncology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

38

2.6K

2

Health Sciences

12

13

932

3

Engineering

6

6

157

4

Arts

1

1

40

5

Natural Sciences

1

1

55

Günter Henze

×

103

Publications

9.9K

Citations

46

H-Index

YearCitations

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi,

Blood

2010

778

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

Martin Schrappe, Alfred Reiter, Wolfgang Ludwig,

PubMed

2000

609

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Anja Möricke, Alfred Reiter, Martin Zimmermann,

Blood

2008

601

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

Alfred Reiter, Martin Schrappe, Markus Tiemann,

PubMed

1999

404

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

Frank Berthold, Joachim Boos, Stefan Burdach,

The Lancet Oncology

2005

397

Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter Trial

Thomas Völker, Timm Denecke, Ingo G. Steffen,

Journal of Clinical Oncology

2007

393

Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Alfred Reiter, Martin Schrappe, Wolfgang Ludwig,

PubMed

2000

365

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

Peter Bader, Hermann Kreyenberg, Günter Henze,

Journal of Clinical Oncology

2008

358

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

Gesche Tallen, Richard Ratei, Georg Mann,

Journal of Clinical Oncology

2010

310

Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87

Hagen Graf Einsiedel, Arend von Stackelberg, R. Hartmann,

Journal of Clinical Oncology

2005

286

Page 1